“Following our launch in Japan in 2025, we expect additional global launches of TEPEZZA in 2026 and beyond.”

In context

“25,000 patients have been treated since launch with growing interest from both new and returning prescribers, increased prescribing from endocrinologists and a broadening specialist base. We see rising awareness of moderate thyroid eye disease in the U.S. This positions TEPEZZA for growth, supported by its best-in-class efficacy, well-established safety profile, industry-leading patient services, and broad payer coverage. We are also encouraged by the positive Phase III data for the on-body injector, which demonstrated comparable efficacy to IV TEPEZZA and supports a clear path to subcutaneous administration without compromising clinical benefit. This convenient dosing option will enable TEPEZZA administration in additional sites of care and expand access for more patients in the future. Following our launch in Japan in 2025, we expect additional global launches of TEPEZZA in 2026 and beyond. TADNIO sales were $119 million in the first quarter, up 32% year over year driven by strong volume growth. Since its launch in 2021, more than 8,000 patients have been treated with Tavneos, and Jay will comment on recent regulatory events in just a few moments. Our innovative oncology portfolio, which consists of Blincyto and Deltra, Vectibix, Kyprolis, Lumicraz and Enflate, grew 25% year over year generating $1.8 billion of sales in the first quarter. INDELTA delivered $258 million in first quarter sales driven by deep clinical conviction and continued adoption across care settings. More than 1,800 U.S. sites now administer Imdeltra with a majority of doses delivered in the community setting. This progress has been supported by the combined efforts of our commercial, medical, and access”